BIOLASE, INC: management transactions · United States · SEC (Form 4)

About BIOLASE, INC

BIOLASE, Inc. is a U.S.-based medical device company listed on NASDAQ in the United States. It focuses on proprietary dental laser systems and related innovation for oral healthcare. The company has long positioned itself as a global leader in dental laser technology, with a product strategy centered on the Waterlase platform and other laser-based systems designed to support minimally invasive dental procedures. Its core value proposition is built around clinical performance, patient comfort, and differentiated treatment outcomes versus conventional tools. ([biolase.com](https://www.biolase.com/about-us/?utm_source=openai)) The company’s origins date back to 1984, when it was founded in Marseille, France, as Societe Endo Technic, SA. Over time, it evolved into BIOLASE Technology, Inc., and later changed its name to BIOLASE, Inc. in 2012. That history underscores a long-standing specialization in advanced dental technology rather than a broad diversified medtech model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/811240/000119312503082455/ds3a.htm?utm_source=openai)) From an operating standpoint, BIOLASE develops and markets dental laser systems across two broad historical product categories: Waterlase systems for all-tissue applications and diode lasers for soft-tissue procedures. The company has also described efforts to expand its clinical applications and introduce new solutions adjacent to dentistry. A meaningful part of its competitive edge comes from intellectual property, with SEC disclosures citing a large portfolio of active patents and pending technologies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/811240/000156459019006918/biol-10k_20181231.htm?utm_source=openai)) BIOLASE competes in a niche segment of the dental equipment market where adoption depends on clinician education, treatment economics, and evidence of better patient experience. The company has highlighted relationships with research institutions, dental schools, and laboratories, which support training, clinical validation, and market awareness. Its headquarters are in Lake Forest, California, reinforcing its U.S. operational base even as its products have historically been sold internationally. ([sec.gov](https://www.sec.gov/Archives/edgar/data/811240/000095017024034812/biol-20231231.htm?utm_source=openai)) Recent company developments are important for investors. In 2025, BIOLASE announced a new chapter following its acquisition by MegaGen Implant, presenting the transaction as a strengthening of its strategic position and future growth platform in dental laser technology. At the same time, recent SEC filings point to a challenging operating backdrop: intense competition, pricing pressure, regulatory and FDA-related risks, patent litigation, and going-concern uncertainty in prior periods. For international investors, BIOLASE remains a specialized, higher-risk medtech name with upside tied to commercial execution and the ability to monetize its laser dentistry franchise more effectively. ([biolase.com](https://www.biolase.com/press-release-biolase-emerges-stronger-than-ever-under-new-ownership-by-megagen-implant/?utm_source=openai))